- Amarin ( NASDAQ: AMRN ) on Wednesday said UK's National Institute for Health and Care Excellence (NICE) had issued its final guidance recommending the company's Vazkepa medicine for reimbursement and use across the national health service in England and Wales.
- Vazkepa is used to reduce the risk of heart attack, stroke and cardiovascular disease.
- NICE recommended a price of £144.21 per 120 soft capsules of Vazkepa.
- Following NICE's final guidance, all local national health service formularies in England and Wales will need to make Vazkepa available within 90 and 60 days, respectively.
- AMRN said it is also in reimbursement discussions in other European markets and remains on track to get pricing decisions in up to eight countries.
- AMRN stock -0.7% to $1.39 in early trading.
For further details see:
Amarin's Vazkepa medicine gets final guidance from UK body for reimbursement and use